On Jun. 22, 2020, Pfizer announced the initiation of four phase 3 clinical trials within its current pipeline of investigational vaccines: Two studies (NCT04382326 and NCT04379713) of the 20-valent pneumococcal polysaccharide conjugate vaccine candidate, 20vPnC, evaluating a four-dose series in infants starting at 2 months of age. One study of the respiratory syncytial virus (RSV) vaccine candidate, and one study of the pentavalent meningococcal vaccine candidate, MenABCWY, in adolescents and young adults.